Innovative
miRNA Therapies

Transforming Infectious Disease Treatment

NorthMiRs uses cutting-edge miRNA-based therapies to fight infectious diseases and save lives.

Our Vision & Mission

We are developing scalable, transformative therapies for sepsis using nanotechnology to deliver microRNA-modulating treatments.

By targeting the immune dysregulation underlying systemic infection, we address the root cause of this deadly condition, moving beyond symptom management.

Our advanced delivery systems enable precise intervention in sepsis’s molecular mechanisms, offering unprecedented therapeutic control in critical care.

Ultimately, we aim to transform ICU outcomes-reducing mortality, easing caregiver burdens, and shifting sepsis treatment from reactive stabilization to proactive immune recovery, ultimately saving lives globally.

To develop scalable, transformative therapies for sepsis using nanotechnology-enabled miRNA delivery.

We are committed to addressing the underlying immune dysregulation of systemic infection using advanced nanotechnology-enabled therapies.

By leveraging microRNA modulating therapies, we aim to transform ICU care for patients and caregivers, ultimately saving lives.

The Challenge of Sepsis

Sepsis is a life-threatening, systemic immune response to infection, often leading to multi-organ failure. It is the most common cause of death in critically ill patients and the most expensive reason for hospitalization.

The current standard of care for sepsis is inadequate, leaving many patients at risk.

NorthMiRs aims to change this.

Our Solution:
NM-001

Building on 15 years of research in mesenchymal stem cell therapy, NorthMiRs has refined a scalable, synthetic therapeutic miRNA enabled by lipid nanoparticle technology.

Our lead candidate, NM-001, regulates immune responses, offering anti-inflammatory, anti-microbial, and organ-protective properties to septic patients, maximizing the chance of survival and speed up patient recovery.

Meet Our Experts

Our team is comprised of leading experts in formulation and preclinical research. From formulation to clinic, NorthMiRs’ specialists ensure every aspect of our therapy is developed with precision and care.

Claudia dos Santos, MD

Claudia dos Santos, MD

Samantha McWhirter

Samantha McWhirter

Gilbert Walker, PhD

Gilbert Walker, PhD

Logan Zettle, MSc

Logan Zettle, MSc

Amin Ektesabi, PhD

Amin Ektesabi, PhD

Chirag Vaswani, PhD

Chirag Vaswani, PhD

Jim Tsoporis, PhD

Jim Tsoporis, PhD

Daniel Weiss, MD

Daniel Weiss, MD

Richard Bozzato, PhD

Richard Bozzato, PhD

Vigen Nazarian, MSc

Vigen Nazarian, MSc

Anna Metcalfe, RAC

Anna Metcalfe, RAC